Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Alm

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Mabs|June 22, 2022
Antigenic landscapes on <i>Staphylococcus aureus</i> pore-forming toxins reveal insights into specificity and cross-neutralizationShweta Kailasan, Ravi Kant, Madeleine Noonan-Shueh, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2015
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpCSushmita D Lahiri, Grant K Walkup, James D Whiteaker, et al.
Journal of Medicinal Chemistry|July 12, 2012
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profileFolkert Reck, Richard A Alm, Patrick Brassil, et al.
Antimicrobial Agents and Chemotherapy|November 12, 2014
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteriaMichael D Huband, Patricia A Bradford, Linda G Otterson, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2022
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is NeededMark S Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2022
Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"Mark S Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2024
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gapsValeria Gigante, Richard A Alm, Daniela Melchiorri, et al.
Molecular Microbiology|April 23, 2004
Characterization of a complex chemosensory signal transduction system which controls twitching motility in Pseudomonas aeruginosaCynthia B Whitchurch, Andrew J Leech, Michael D Young, et al.
Scientific Reports|September 19, 2015
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Mabs|June 22, 2022
Antigenic landscapes on <i>Staphylococcus aureus</i> pore-forming toxins reveal insights into specificity and cross-neutralizationShweta Kailasan, Ravi Kant, Madeleine Noonan-Shueh, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2015
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpCSushmita D Lahiri, Grant K Walkup, James D Whiteaker, et al.
Journal of Medicinal Chemistry|July 12, 2012
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profileFolkert Reck, Richard A Alm, Patrick Brassil, et al.
Antimicrobial Agents and Chemotherapy|November 12, 2014
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteriaMichael D Huband, Patricia A Bradford, Linda G Otterson, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2022
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is NeededMark S Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2022
Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"Mark S Butler, Valeria Gigante, Hatim Sati, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2024
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gapsValeria Gigante, Richard A Alm, Daniela Melchiorri, et al.
Molecular Microbiology|April 23, 2004
Characterization of a complex chemosensory signal transduction system which controls twitching motility in Pseudomonas aeruginosaCynthia B Whitchurch, Andrew J Leech, Michael D Young, et al.
Scientific Reports|September 19, 2015
Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Pageof 5